



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C07D 211/34</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 97/32851</b> <b>(43) International Publication Date:</b> 12 September 1997 (12.09.97)
<b>(21) International Application Number:</b> PCT/GB97/00643 <b>(22) International Filing Date:</b> 7 March 1997 (07.03.97)  <b>(30) Priority Data:</b> 9604943.2              8 March 1996 (08.03.96)              GB 60/016,986            7 May 1996 (07.05.96)              US  <b>(71) Applicant (for all designated States except US):</b> MEDEVA EUROPE LIMITED [GB/GB]; 10 St. James's Street, London SW1A 1EF (GB).  <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only):</b> ZAVAREH, Hooshang, Shahriari [GB/GB]; Chiroscience Limited, Cambridge Sci- ence Park, Milton Road, Cambridge CB4 4WE (GB).  <b>(74) Agent:</b> GILL JENNINGS & EVERY; Broadgate House, 7 Eldon Street, London EC2M 7LH (GB).		<b>(81) Designated States:</b> AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> RESOLUTION OF THREO-METHYLPHENIDATE  <b>(57) Abstract</b>  A process for preparing substantially single enantiomer <i>d-threo</i> -methylphenidate, proceeds by means of a classical salt resolution using (-)-menthoxyacetic acid.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

## RESOLUTION OF *THREO*-METHYLPHENIDATE

### Field of the Invention

This invention relates to the resolution of *threo* methylphenidate via crystallisation of diastereomeric salts.

### 5 Background of the Invention

Methylphenidate was first prepared as a mixture of the *erythro* and *threo* racemates. US-A-2957880 discloses studies upon the two racemic mixtures, which revealed that the therapeutic activity resides in the *threo* diastereomer.

The resolution of *threo* methylphenidate can be achieved using the expensive  
10 resolving agent 1,1'-binaphthyl-2,2'-diylhydrogen phosphate, a process first reported by Patrick *et al* (The Journal of Pharmacology and Experimental Therapeutics, 241:152-158 (1987)), and subsequently used by other workers in the field (e.g. Aoyama *et al*, Journal of Chromatography, 494:420 (1989)). This is perceived to be a more efficient procedure than the method disclosed in US-A-2957880, wherein the corresponding amide of  
15 *erythro* methylphenidate (i.e. R-CONR<sub>2</sub> rather than R-CON<sub>2</sub>Me) is resolved with tartaric acid prior to amide hydrolysis and equilibration at the benzylic centre, followed by esterification of the resultant *threo*-acid.

An improved resolution process is described in PCT/GB97/00185. Such a resolution can be combined with the racemisation described in PCT/GB97/00281.

### 20 Summary of the Invention

This invention is based upon the discovery that racemic *threo* methylphenidate can be resolved using inexpensive (-)-menthoxyacetic acid.

### Description of the Invention

The process of this invention may be carried out under conditions that are  
25 generally known to those skilled in the art of classical salt resolution procedures. For example, a mixture of *threo* methylphenidate free base and 1 molar equivalent of (-)-menthoxyacetic acid in an inert organic solvent is heated and then allowed to cool; the resultant precipitate is filtered, washed with an appropriate solvent and dried to afford directly a salt enriched in 98% ee *d-threo* methylphenidate. This is a great improvement  
30 on the literature method using 1,1'-binaphthyl-2,2'-diylhydrogen phosphate, described by Patrick *et al*, *supra*, in which the first crystallisation gave a salt corresponding to 85-90%

ee material, and further recrystallisation of this material was necessary to raise the ee to 95-97%. The latter level of optical purity is achieved in the present invention in one crystallisation, with an overall higher yield. The method of this invention is therefore more efficient and more economical than the one described by Patrick *et al.*

- 5       The following Example illustrates the resolution of *threo* methylphenidate using (-)-menthoxyacetic acid.

Example

- dl-threo* methylphenidate (1.0 g, 3.7 mmol) was suspended in water (20 ml) and treated with caustic solution. The liberated free base was extracted with MTBE (3 x 25  
10 ml), dried over MgSO<sub>4</sub> and evaporated to a light oil. This was dissolved in IPA (15 ml) and heated to 60°C. (-)-Menthoxyacetic acid (0.79 g, 3.79 mmol) in IPA (5 ml) was added. Heating was continued for a further 30 min and the mixture was gradually cooled to 10°C. The resulting white crystalline product was filtered off, washed with cold IPA and dried (0.85 g, 47% by weight, corresponding to 98% ee *d-threo* methylphenidate,  
15 as determined by chiral HPLC after salt cracking).

**CLAIM**

A process for preparing substantially single enantiomer *d-threo*-methylphenidate, which proceeds by means of a classical salt resolution using (-)-menthoxyacetic acid.

# INTERNATIONAL SEARCH REPORT

Internu 1 Application No  
PCT/GB 97/00643

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 C07D211/34

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	J. PHARMACOL. EXP. THER., vol. 241, no. 1, 1987, pages 152-8, XP000612231 PATRICK K. S.; CALDWELL R. W.; FERRIS R. M.; BREESE G.R.: "Pharmacology of the Enantiomers of threo-Methylphenidate" cited in the application see page 153	1
A	--- US 2 957 880 A (ROMETSCH ET AL.) 25 October 1960 cited in the application see example 6 --- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

4 June 1997

Date of mailing of the international search report

20.06.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+ 31-70) 340-3016

Authorized officer

Lauro, P

# INTERNATIONAL SEARCH REPORT

Intern. J Application No

PCT/GB 97/00643

## C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	PATENT ABSTRACTS OF JAPAN vol. 4, no. 73 (C-012), 28 May 1980 & JP 55 038363 A (YOSHITOMI PHARMACEUT. IND.), 17 March 1980, see abstract ---	1
A	US 4 196 303 A (KANE ET AL.) 1 April 1980 see column 1; line 5-20 -----	1

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern: d Application No

PCT/GB 97/00643

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2957880 A	25-10-60	NONE	
US 4196303 A	01-04-80	NONE	